Indian Parliament Panel Urges Rejection Of MNC Anti-Generics Try
This article was originally published in PharmAsia News
Executive Summary
An effort by multinational pharmaceutical companies to get India to require separate research before approving generic versions of their drugs has suffered a setback in the Parliament. A committee urged India's drug authorities to keep the current practice of approving generics that rely on the same chemical composition as a branded version already approved in another country. Under the current rules, Indian generics makers need only refer to the branded drug and show it uses the same chemical makeup if the generic wants to win marketing approval. The committee said changes in the rule were being urged by MNCs with a vested interest in new rules. (Click here for more